Special Issue "Metabolism and Leukemia: From Biology to Therapies"
Deadline for manuscript submissions: 15 September 2021.
Interests: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Target therapy; Monoclonal Antibodies; Mastocytosis; Tyrosine Kinase Inhibitors
Altered metabolism plays a key role in malignancies, and has recently been defined as an emerging hallmark of cancer. This is true also in the setting of haematological neoplasms, including Acute Myeloid and Lymphoblastic Leukemias, which utilize altered metabolism to maximize cell growth and survival. In detail, many studies in literature demonstrated that, in order to maintain cell proliferation, expansion and survival, a reprogramming of metabolism must be performed to satisfy key bioenergetics, biosynthetic, and redox functions of leukemic cells. Furthermore, several metabolites have a signaling function and promote tumor growth and progression. The importance of metabolic adaptation for the survival of AML cells and the therapeutic potential of addressing different metabolic pathways have already been reported. As a consequence, starting from this rationale, in the last few years, several drugs have been developed to target specific metabolic pathways and enzymes, metabolites, and signaling pathways. Several studies, some of which are currently ongoing, have shown an acceptable safety profile of some of these metabolism-affecting drugs, even when used in combination with standard chemotherapy, which still represents the first line therapeutic option for fit AML and ALL patients. Nevertheless, in relapsed settings and in unfit/elderly populations, innovative therapeutic options are strongly required, and targeting metabolism may represent an attractive tool.
In this Special Issue, we're going to highlight the most recent data in the field, from biological setting to therapeutic implications.
Dr. Cristina Papayannidis
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- PI3K AKT